FDA Approves Shire's Projected Blockbuster HAE Treatment Takhzyro

The FDA has approved Shire’s Takhzyro™ (lanadelumab-flyo), enabling the biotech giant to deliver on years of forecasts that the first-of-its-kind preventive hereditary angioedema (HAE) treatment will prove a blockbuster for the biotech giant as it prepares to be acquired by Takeda Pharmaceutical.Takhzyro is a monoclonal antibody (mAb) injected into patients and designed to work by specifically binding and decreasing plasma kallikrein. Takhzyro is indicated to prevent HAE attacks in p